These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37926243)

  • 21. Nanoparticles for direct nose-to-brain delivery of drugs.
    Mistry A; Stolnik S; Illum L
    Int J Pharm; 2009 Sep; 379(1):146-57. PubMed ID: 19555750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucoadhesive Nanosystems for Nose-to-Brain Drug Delivery in the Treatment of Central Nervous System Diseases.
    Di Filippo LD; Duarte J; Fonseca-Santos B; Tavares Júnior AG; Araújo V; Roque Borda CA; Vicente EF; Chorilli M
    Curr Med Chem; 2022; 29(17):3079-3110. PubMed ID: 34391374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.
    Mignani S; Shi X; Karpus A; Majoral JP
    Eur J Med Chem; 2021 Jan; 209():112905. PubMed ID: 33069435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory.
    Merkus FW; van den Berg MP
    Drugs R D; 2007; 8(3):133-44. PubMed ID: 17472409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal delivery: circumventing the iron curtain to treat neurological disorders.
    Jiang Y; Li Y; Liu X
    Expert Opin Drug Deliv; 2015; 12(11):1717-25. PubMed ID: 26206202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: An overview.
    Song YH; De R; Lee KT
    Adv Colloid Interface Sci; 2023 Oct; 320():103008. PubMed ID: 37776736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications.
    Xu K; Duan S; Wang W; Ouyang Q; Qin F; Guo P; Hou J; He Z; Wei W; Qin M
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1956. PubMed ID: 38558503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review.
    Phukan K; Nandy M; Sharma RB; Sharma HK
    Recent Pat Drug Deliv Formul; 2016; 10(2):156-64. PubMed ID: 26996366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration.
    Kadakia E; Bottino D; Amiji M
    Pharm Res; 2019 Mar; 36(5):75. PubMed ID: 30923914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comprehensive Review on Nanomedicine: Promising Approach for Treatment of Brain Tumor through Intranasal Administration.
    Bahadur S; Prakash A
    Curr Drug Targets; 2023; 24(1):71-88. PubMed ID: 36278468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin.
    Tashima T
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33171799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective.
    Nishihara H; Engelhardt B
    Handb Exp Pharmacol; 2022; 273():295-329. PubMed ID: 33237504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From nose to brain: understanding transport capacity and transport rate of drugs.
    Wu H; Hu K; Jiang X
    Expert Opin Drug Deliv; 2008 Oct; 5(10):1159-68. PubMed ID: 18817519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanocarrier-mediated curcumin delivery: An adjuvant strategy for CNS disease treatment.
    Godse S; Zhou L; Sakshi S; Singla B; Singh UP; Kumar S
    Exp Biol Med (Maywood); 2023 Nov; 248(22):2151-2166. PubMed ID: 38058006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation considerations for improving intranasal delivery of CNS acting therapeutics.
    Patel D; Thakkar H
    Ther Deliv; 2022 Jul; 13(7):371-381. PubMed ID: 36416617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.
    Ross TM; Martinez PM; Renner JC; Thorne RG; Hanson LR; Frey WH
    J Neuroimmunol; 2004 Jun; 151(1-2):66-77. PubMed ID: 15145605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.